Cas:460-63-9 1,3,3-trichloro-1,1-difluoropropane manufacturer & supplier

Chemical Name:1,3,3-trichloro-1,1-difluoropropane

CAS.NO:460-63-9

Synonyms:1,1-Difluoro-1,3,3-trichloropropane;1,1,3-trichloro-3,3-difluoropropane;1,3,3-trichloro-1,1-difluoro-propane;1,3,3-Trichlor-1,1-difluor-propan;HCFC-242

Molecular Formula:C₃H₃Cl₃F₂

Molecular Weight:183.41200

HS Code:2903791090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:114.9ºC at 760mmHg

Density:1.484g/cm3

Index of Refraction:1.412

PSA:

Exact Mass:181.92700

LogP:3.01180

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1,1-Difluoro-1,3,3-trichloropropane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,HCFC-242 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,1,3-trichloro-3,3-difluoropropane Use and application,1,3,3-trichloro-1,1-difluoro-propane technical grade,usp/ep/jp grade.

Related News: A week after the memo was released to employees, Reuters reported that the Justice Department had launched a criminal investigation focused on the Branchburg plant. That same day, May 27, Lilly reported to the U.S. Securities and Exchange Commission that it had received a subpoena from the department seeking documents related to the factory. 1,3,3-trichloro-1,1-difluoropropane manufacturer For Jefferies, this “has not been demonstrated to convincingly reduce Abeta plaque burden, in our view.” The firm forecasts $3 billion in global sales for gantenerumab, but at a striking 0%, “so probability so no contribution.” 1,3,3-trichloro-1,1-difluoropropane supplier CMO services mainly involve four stages: pre-clinical research, clinical trials, sales of patented drugs after listing, and sales of original drug products after patents expire. Its advantages are: lower cost, guaranteed quality, good capacity flexibility, and favorable process Promotion. 1,3,3-trichloro-1,1-difluoropropane vendor ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy. 1,3,3-trichloro-1,1-difluoropropane factory A week after the memo was released to employees, Reuters reported that the Justice Department had launched a criminal investigation focused on the Branchburg plant. That same day, May 27, Lilly reported to the U.S. Securities and Exchange Commission that it had received a subpoena from the department seeking documents related to the factory.